Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF

NCT00156780 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2006-10-23

No results posted yet for this study

Summary

This study was conducted to evaluate the safety and pharmacokinetics of an echocardiographic contrast agent, AI-700, in patients with moderate to severe chronic obstructive pulmonary disease (COPD) and/or congestive heart failure (CHF).

Conditions

Interventions

DRUG

AI-700

Sponsors & Collaborators

  • Acusphere

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
ECT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Completion
2005-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00156780 on ClinicalTrials.gov